Vardenafil,
does it really help with Improved IIEF erectile function and penetration and intercourse success rates in men with erectile dysfunction?
research showsVardenafil is rated B. A meta-analysis of 14 short-term randomized trials with 3,221 participants found large placebo-adjusted improvements of 7.93 IIEF-EF points, 26.36 percentage points in SEP2 penetration success, and 35.18 percentage points in SEP3 intercourse success. The evidence base is nevertheless about 3,000 participants, mostly short term, roughly 70% industry linked, and overlapping across development-program analyses. It therefore falls short of the tens of thousands of participants, dozens of trials, and independent replication expected for A, while the large direct effects justify the top of B at 79 points.
ads claimMarketing may imply that one pill permanently restores confidence, relationships, or masculinity, or causes an automatic erection without stimulation. The drug requires sexual stimulation and correct use, improves erectile response during a dosing episode, and does not remove the underlying cause.
Useful facts when choosing a product
- Vardenafil is a prescription PDE5 inhibitor generally taken as needed before sexual activity, and sexual stimulation is required for it to work. The prescribed starting dose, interval, and product instructions take priority.
- Combining it with nitrates or nitric-oxide donors can cause life-threatening hypotension and is absolutely contraindicated. It must not be combined with riociguat either.
- Common adverse effects include headache, flushing, nasal congestion, dyspepsia, and dizziness; visual change, hearing loss, chest pain, or an erection lasting four hours or longer requires urgent care.
- Strong CYP3A4 inhibitors, alpha blockers, QT-prolongation risk, and cardiovascular fitness require review before prescribing, while undeclared PDE5 drugs in online sexual supplements are a separate safety problem from authentic prescription medicine.
What the research actually shows
Wang 2021 meta-analyzed 14 randomized trials with 3,221 participants and found significant benefits across IIEF domains and SEP2 and SEP3. The Eardley 2010 integrated analysis found consistent efficacy across comorbidities, but substantial overlap with the same development program means it is not a separate large independent replication. In the enriched-design Valiquette 2005 trial, 12-week penetration success was 83.4% versus 55.8%, erection-maintenance success was 76.6% versus 42.1%, and IIEF-EF was 23.5 versus 15.8 with vardenafil versus placebo. The effects are large and direct, while evidence scale, duration, and independence remain one step below A.
Why this is classified as B (79)
A meta-analysis of 14 randomized trials with 3,221 participants showed large direct improvements of 7.93 IIEF-EF points, 26.36 percentage points in SEP2, and 35.18 percentage points in SEP3. The evidence base is about 3,000 participants in short trials, roughly 70% industry linked, with overlap across development-program analyses. This falls short of the large-scale independent A standard, while the large patient-centered effects support B with 79 points. The nitrate interaction remains a separate safety issue.
Counterpoint. If response is inadequate, clinicians should review food timing, sexual stimulation, dose timing, number of attempts, and dose, and evaluate vascular disease, diabetes, low testosterone, medicines, and psychological factors. Self-escalation or combining PDE5 inhibitors should be avoided.
Rejudgment record. Cross-check revision — Assigned the top of B because large direct effects of 7.93 IIEF-EF points, 26.36 percentage points in SEP2, and 35.18 percentage points in SEP3 are supported by about 3,000 participants in 14 short trials, but roughly 70% industry linkage and development-program overlap fall short of the large-scale independent A standard
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in the IIEF erectile-function domain | B | A 14-trial short-term meta-analysis found a large placebo-adjusted mean improvement of 7.93 points, but industry linkage and program overlap limit independence. |
| Improvement in penetration success | B | SEP2 was 26.36 percentage points higher than placebo, but evidence is concentrated in short, industry-linked trials involving about 3,000 participants. |
| Improvement in erection maintenance and intercourse success | B | SEP3 improved by 35.18 percentage points versus placebo, but evidence centers on short development trials. The effect is on-demand and requires sexual stimulation. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Wang H et al. 2021 | Systematic review and meta-analysis of randomized controlled trials | 3,221 | Academic meta-analysis; included development trials may be industry-concentrated | IIEF domains and SEP2 penetration and SEP3 erection-maintenance or intercourse success | Significant placebo-adjusted improvements of 7.93 IIEF-EF points, 26.36 percentage points in SEP2, and 35.18 percentage points in SEP3. | Key direct synthesis limited by short duration and industry concentration |
| Eardley I et al. 2010 | Retrospective integrated analysis of 13 randomized double-blind placebo-controlled trials | 4,143 | Vardenafil development program with pharmaceutical-company authors | IIEF-EF, SEP2, SEP3, and responses by comorbidity | At 12 weeks, all overall and comorbidity subgroups improved significantly versus placebo. | Large consistency assessment |
| Valiquette L et al. 2005 | Randomized double-blind placebo-controlled enriched-design trial | 523 | Product-development trial with industry linkage | SEP2, SEP3, IIEF-EF, and global improvement | At 12 weeks, penetration success was 83.4% versus 55.8%, maintenance success 76.6% versus 42.1%, and IIEF-EF 23.5 versus 15.8 in favor of vardenafil. | Large direct effect limited by responder enrichment |
| Burnett AL et al. 2018 AUA guideline | Clinical guideline based on a systematic evidence review | 2017 | American Urological Association | Patient-centered treatment choices, benefits, and harms | Presents established options including PDE5 inhibitors through shared decision-making. | Standard-care context, not the grade basis itself |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Vardenafil x improved erectile function, penetration, and intercourse success — Evidence Grade B·79. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/vardenafil-erectile-function-penetration-intercourse-success/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.